In previous studies by our group and others, methdilazine (Md), an extensively used antihistaminic phenothiazine, demonstrated broad-spectrum antibacterial activity (Chattopadhyay et al., 1988 (Chattopadhyay et al., , 1998 Basu et al., 2005) . Md also inhibited various Mycobacterium spp. at 5-15 mg l 21 in vitro and in vivo (Chakrabarty et al., 1993) . It has been reported to act by enhancement of streptomycin (Sm) or kanamycin activity against Escherichia coli and Staphylococcus aureus (Chattopadhyay et al., 1988) , and by damaging the bacterial cytoplasmic membrane (Chattopadhyay et al., 1998) or, like other phenothiazines, by reversing clinical resistance and inhibiting efflux pumps (Amaral et al., 2008) .
Patients undergoing therapy for tuberculosis are often administered Md as an antihistamine. Keeping that in mind, this study was undertaken to examine the possible effects of Md combined with the first-line antitubercular drugs isoniazid (INH) or Sm in the treatment of murine tuberculosis.
Four-week-old Swiss albino male mice were infected intravenously with 2.3610 7 c.f.u. naturally virulent Mycobacterium tuberculosis (Mtb) H37Rv 102 per mouse as previously described (Dutta et al., 2005 (Dutta et al., , 2007 Group 2 was administered 0.1 ml sterilized PBS instead of drug for those days. On the day after inoculation, seven mice (day 1 control) were sacrificed to provide the baseline values of spleen weight, and the number of c.f.u. in the lungs and spleen. The last dose of treatment was given on day 28 and all surviving mice were sacrificed on day 30 to reduce the carryover effects of drugs in the organs. The severity of infection and the effectiveness of treatment were assessed by the survival rate, spleen weights, gross lung lesions (0, no lesions; +, fewer than 10 tubercles; ++, 10-50 tubercles; +++, more than 50 tubercles) and the c.f.u. count in the organs. The enumeration of c.f.u. from aseptically removed and homogenized lungs and spleens of sacrificed and dead mice was carried out as previously described (Dutta et al., 2005 (Dutta et al., , 2007 .
Untreated control mice began to die from day 14, and all mice died of tuberculosis before day 28, as the mice harboured lung lesions (++ to +++), showed reduced body weight and splenomegaly ( (Chakrabarty et al., 1993; Dutta et al., 2005 Dutta et al., , 2007 Martins et al., 2007; Mazumdar et al., 2009) . In a published study, Md injected intraperitoneally at 10 mg kg 21 daily for 1 month to mice could significantly (P,0.01) protect them from challenge with (4.5610 9 c.f.u.) Mtb H37RV (Chakrabarty et al., 1993) . It corroborates the reported curative activity of phenothiazine thioridazine (0.5 mg daily for 1 month) on mice infected with Mtb (10 6 c.f.u.) (Martins et al., 2007) .
Today it is widely discussed that phenothiazines might be considered for use as adjuvants for the management of tuberculosis infection due to their ability to kill intracellular antibiotic-sensitive/ -resistant Mtb when used at concentrations in the medium well below those present in the plasma of patients treated with these agents. These concentrations in vitro were not toxic to the macrophage, nor did they affect in vitro cellular immune processes Amaral et al., 2008) . The intrinsic resistance of Mycobacterium avium and Mycobacterium smegmatis is affected by antimycobacterial phenothiazine efflux pump inhibitors, such as thioridazine or chlorpromazine, an effect that might be important in the research and development of new, more effective antimycobacterial therapies (Rodrigues et al., 2008 
